Table 3 Primary feasibility outcome measurements
Outcome | Progression criteria. Total number (unless stated as %) | Outcome in the trial%, (95% CI) |
|---|---|---|
Number expressing interest | At least 180 individuals | 350 Achieved |
Number recruited | At least 60 participants | 75 (21.43% of those that expressed interest recruited (17.43 to 26.06)) Achieved |
Number randomised | At least 60 participants | 60 (80% (69.23 to 87.67) of the recruited 75 participants) Achieved |
Percentage of participants lost to follow up |  ≤ 40% | 8.4% (3.45 to 18.80) Achieved |
Percentage of participants deemed unsuitable for, and did not commence, therapy | New observation during trial-no progression criteria established at outset | 11.7% (5.58 to 22.80) |
Completeness of all outcome data for all randomised participants (Missing data point/All data points at 20 weeks) |  ≥ 60% | 75% (62.29 to 84.49) Achieved |
Completeness of PCL-5 outcome at 20 weeks |  ≥ 60% | 75% (62.29 to 84.49) Achieved |
Compliance with therapy | RTM compliance ≥ 70% TFCBT compliance ≥ 50% | 60%(46.96 to 71.76) Partially Achieved |